Jazz Pharmaceuticals to acquire GW Pharmaceuticals in $7.2bn deal
In a significant move within the pharmaceutical industry, Irish biopharma company Jazz Pharmaceuticals has announced an agreement to acquire British-based GW Pharmaceuticals in a monumental ... Read More
Horizon Therapeutics announces $3.05bn acquisition of Viela Bio to expand rare disease pipeline
In a major move to strengthen its leadership in rare diseases, Horizon Therapeutics, an Irish biopharmaceutical company, has agreed to acquire Viela Bio, a US-based ... Read More
Nordic Capital proposes $846m acquisition of Advanz Pharma
In a significant move within the pharmaceutical industry, Nordic Capital has made a formal offer to acquire Advanz Pharma, a UK-based specialty pharmaceutical company, for ... Read More
Thermo Fisher Scientific acquires Henogen from Novasep for €725m to expand viral vector manufacturing capabilities
Thermo Fisher Scientific has completed the acquisition of Henogen, a viral vector manufacturing business previously owned by Groupe Novasep, for €725 million in cash. This ... Read More
Sanofi signs $1.45bn deal to acquire Kymab, expanding its immune-therapy pipeline
In a significant move to bolster its immuno-oncology and immune-mediated disease portfolio, Sanofi has acquired Kymab, a UK-based clinical-stage biopharma company, in a deal valued ... Read More
Novartis to expand neuroscience portfolio with $770m acquisition of Cadent Therapeutics
In a bold move to strengthen its neuroscience division, Swiss pharmaceutical giant Novartis has agreed to acquire Cadent Therapeutics, a US-based neuroscience company, in a ... Read More
Eli Lilly to acquire Prevail Therapeutics for $1.04bn, expanding gene therapy pipeline
Eli Lilly and Company has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a prominent US gene therapy company specializing in ... Read More
EQT Partners offers $2.8bn takeover bid for Swedish pharma giant Recipharm
Swedish private equity firm EQT Partners has made a bold move in the pharmaceutical sector, offering to acquire Recipharm, a leading contract development and manufacturing ... Read More
AstraZeneca signs $39bn deal to acquire Alexion Pharmaceuticals
In a landmark move that’s poised to shake up the world of immunology and rare disease treatments, AstraZeneca has sealed a $39 billion deal to ... Read More
Gilead Sciences acquisition of MYR: A strategic move to tackle hepatitis delta virus
In a strategic acquisition aimed at expanding its hepatitis treatment portfolio, US biopharmaceutical giant Gilead Sciences has announced the acquisition of MYR GmbH, a German ... Read More